Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.06% Nasdaq Down0.01%

Auxilium Pharmaceuticals Inc. (AUXL)

-NasdaqGS

15.18 Down 0.08(0.52%) May 24, 4:00PM EDT|After Hours : 15.37 Up 0.19 (1.28%) May 24, 5:52PM EDT

Add to Portfolio
ProfileGet Profile for:
Auxilium Pharmaceuticals Inc.
640 Lee Road
Malvern, PA 19087
United States - Map
Phone: 484-321-5900
Fax: 484-321-5999
Website: http://www.auxilium.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Related Products
Full Time Employees:526

Business Summary 

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, together with its subsidiaries, develops and markets pharmaceutical products worldwide. It markets Testim, a topical 1% testosterone once-a-day gel for the treatment of hypogonadism; and XIAFLEX, an injectable clostridial collagenase enzyme for the treatment of Dupuytren’s in adult patients with a palpable cord. The company is also developing XIAFLEX, which is in Phase III clinical trial for the treatment of Peyronie’s disease; and in Phase II clinical trial for the treatment of Adhesive Capsulitis, as well as in Phase II clinical trial for the treatment of edematous fibrosclerotic panniculopathy. In addition, it is developing a high concentration testosterone gel product. Further, the company has rights to pursue additional indications for collagenase clostridium histolyticum. Auxilium Pharmaceuticals, Inc. sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors, and chain drug stores. The company was founded in 1999 and is headquartered in Chesterbrook, Pennsylvania.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Auxilium Pharmaceuticals Inc.

Corporate Governance 
Auxilium Pharmaceuticals Inc.’s ISS Governance QuickScore as of May 1, 2013 is 4. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 5; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Adrian Adams , 62
Chief Exec. Officer, Pres and Director
1.31M0.00
Mr. James E. Fickenscher , 49
Chief Financial Officer and Principal Accounting Officer
557.00K0.00
Mr. Andrew I. Koven , 55
Chief Admin. Officer, Exec. VP, Gen. Counsel and Sec.
690.00K0.00
Mr. Alan J. Wills , 50
Exec. VP of Corp. Devel.
532.00K0.00
Dr. James Patrick Tursi M.D., 48
Chief Medical Officer
543.00K0.00
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders